Report cover image

Dementia with Diabetes Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146897

Description

Around 30% of people aged 65 and above have diabetes in the United States, according to the American Diabetes Association. Diabetes patients experience a greater risk of developing dementia as compared to people without diabetes. A study has shown that Type 1 diabetics are 93% more likely to be affected by dementia. Thus, the rising burden of diabetes and its association with dementia is augmenting the need for treatments that can address both conditions. This growing demand is likely to lead to significant investments in expanding the drug pipeline and manufacturing capacities.

Report Coverage

The Dementia with Diabetes Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into dementia with diabetes drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dementia with diabetes. The dementia with diabetes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dementia with diabetes pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dementia with diabetes treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dementia with diabetes.

Dementia with Diabetes Drug Pipeline Outlook

Diabetes is considered a major risk factor for dementia, which is stimulating the development of novel dementia with diabetes therapeutics. It is reported that type 2 diabetes patients are prone to developing dementia, particularly vascular dementia. Studies have shown that low blood sugar level or hypoglycemia is linked to brain cell degeneration and cognitive decline whereas high blood sugar levels are associated with Alzheimer's disease.

For the management of diabetes in individuals with dementia, some diabetes drugs can help slow the progression of dementia and enhance cognitive function. In some studies, metformin is reported to decrease the risk of memory and thinking problems. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used primarily for type 2 diabetes, may also reduce the risk of dementia. With substantial investments by pharmaceutical companies, adherence to dementia with diabetes treatment guidelines, and the growing focus on targeted therapies, the drug pipeline is expected to expand in the coming years.

Dementia with Diabetes Epidemiology

Recent epidemiological studies have suggested the increasing prevalence and incidence of dementia in diabetes patients. Several meta-analyses have estimated that diabetes increases the risk of dementia by nearly half among the patient population.

According to a study published in Diabetes Care (2024), people diagnosed with diabetes in middle age have a higher lifetime risk of dementia (36%) compared to those diagnosed later in life (31%). By age 80, the dementia incidence is also higher in middle age-onset diabetes cases (16.1%) compared to those without diabetes (9.4%). Moreover, dementia tends to appear 4 years earlier for people with middle age-onset diabetes compared to those without diabetes.

Dementia with Diabetes – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of dementia with diabetes drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Proteins and Peptides
  • Small Molecules
  • Hormones
  • Enzymes
By Route of Administration
  • Oral
  • Parenteral
  • Others
Dementia with Diabetes – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of dementia with diabetes emerging drugs.

Dementia with Diabetes – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under dementia with diabetes pipeline analysis include proteins and peptides, small molecules, hormones, and enzymes. The dementia with diabetes report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dementia with diabetes.

Dementia with Diabetes Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for dementia with diabetes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dementia with diabetes therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dementia with diabetes clinical trials:
  • HiDO Technologies
  • Bespoke Clinical Research
  • MD Stem Cells
  • Thomas Advanced Medical LLC
  • Sanguine Biosciences
Dementia with Diabetes – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: Ginkgo Ketone Ester Tablets

The objective of this multicenter randomized double-blind controlled clinical study is to evaluate the efficacy and safety of dementia with diabetes drug candidate Ginkgo biloba ketone ester tablets, containing extracts of Ginkgo biloba leaves, for the treatment of diabetes related dementia in type 2 diabetes patients with mild cognitive impairment. The study is under Phase IV clinical development and has an estimated 370 participants.

Biological: PrimePro™/ PrimeMSK™

This Phase II clinical study is aimed at examining the efficacy, tolerability, and safety of stem cell therapy PrimePro™/ PrimeMSK™ for various chronic and acute conditions including diabetes complications and neurologic or neurodegenerative disorders. The interventional study has enrolled about 5000 subjects and is expected to be completed by December 2030.

Reasons To Buy This Report

The Dementia with Diabetes Drug Report provides a strategic overview of the latest and future landscape of treatments for dementia with diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dementia with diabetes pipeline insights.

Key Questions Answered in the Dementia with Diabetes – Pipeline Insight Report
  • What is the current landscape of dementia with diabetes pipeline drugs?
  • Which companies/institutions are developing dementia with diabetes drugs?
  • How many phase III and phase IV drugs are currently present in dementia with diabetes pipeline drugs?
  • What is the efficacy and safety profile of dementia with diabetes drug candidates?
  • What are the opportunities and challenges present in the dementia with diabetes drug pipeline landscape?
  • What geographies are covered for dementia with diabetes clinical trials?
  • What are emerging therapies in dementia with diabetes clinical trials?
Related Reports

Dementia Drugs Market

Global Diabetes Drugs Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Dementia with Diabetes
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Dementia with Diabetes
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dementia with Diabetes: Epidemiology Snapshot
5.1 Dementia with Diabetes Incidence by Key Markets
5.2 Dementia with Diabetes – Patients Seeking Treatment in Key Markets
6 Dementia with Diabetes: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Dementia with Diabetes: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Dementia with Diabetes, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Dementia with Diabetes Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Dementia with Diabetes Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: DPP-4 inhibitor, Drug: DPP-4 inhibitor + metformin
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Ginkgo Ketone Ester Tablets
10.2.3 Other Drugs
11 Dementia with Diabetes Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Biological: PrimePro™/ PrimeMSK™
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Dementia with Diabetes Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Dementia with Diabetes Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Dementia with Diabetes, Key Drug Pipeline Companies
14.1 HiDO Technologies
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Bespoke Clinical Research
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 MD Stem Cells
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Thomas Advanced Medical LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Sanguine Biosciences
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us